Injectable Depot Formulation for Sustained Small Molecule Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for administering small molecule psychotherapeutic drugs, such as oral pills and bolus injections, result in plasma concentration peaks and troughs, leading to adverse effects and loss of therapeutic efficacy due to variability in drug delivery.
Innovation Solution
An injectable depot formulation comprising a biocompatible polymer and organic solvent forming a viscous gel, which incorporates small molecule drugs, providing a controlled release profile with a Cmax to Cmin ratio less than 200 and lag time less than 0.2, allowing for sustained drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral pills or bolus injections are used to administer small molecule psychotherapeutic drugs, then the administration is simple and convenient, but plasma concentration peaks and troughs occur leading to adverse effects and loss of therapeutic effect
Solution Approach 1:
The drug is pre-loaded into a polymer depot formulation that is designed to release the drug at a controlled rate over time. The polymer matrix is prepared in advance with the drug incorporated, creating a reservoir that gradually releases the medication, thereby eliminating the need for frequent dosing while maintaining stable plasma concentrations.
Solution Approach 2:
The invention changes the physical and chemical parameters of the drug delivery system by using a polymer matrix with specific properties (molecular weight, composition, crosslinking density) that control the diffusion and release rate of the drug. By adjusting these parameters, the release kinetics can be tuned to achieve near-zero-order release and minimize plasma concentration fluctuations.
2Reliability
If sustained release depot formulation is used to minimize plasma concentration variations, then therapeutic effect is maintained and adverse effects are reduced, but the formulation complexity increases
Solution Approach 1:
The invention uses composite material systems combining biocompatible polymers (such as PLGA, PCL, or PGA) with small molecule drugs to create a depot formulation. The polymer matrix provides structural integrity and controlled release properties, while the incorporated drug provides therapeutic effect. This composite approach achieves sustained release functionality through material selection rather than complex mechanical structures.
Solution Approach 2:
The polymer depot formulation utilizes the porous structure inherent in polymer matrices to enable controlled drug diffusion. The porosity of the polymer network allows drug molecules to diffuse out at a controlled rate while maintaining the structural integrity of the depot. This natural porous structure simplifies the formulation compared to requiring additional release mechanisms.
3Reliability
If frequent dosing is administered to maintain therapeutic levels, then plasma concentration is maintained, but patient compliance decreases and adverse effects increase
Solution Approach 1:
The sustained release depot formulation provides continuous drug delivery over an extended period (weeks to months), eliminating the discontinuous dosing schedule of traditional formulations. The polymer matrix continuously releases the drug at a controlled rate, maintaining therapeutic plasma concentrations without requiring repeated patient visits or self-administration, thereby improving compliance while maintaining therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This formulation achieves a near zero-order release profile, minimizing variability in drug concentration and extending therapeutic effects over weeks or months, enhancing patient compliance and reducing adverse effects.
Implementation Method 1
an organic solvent combined with the biocompatible polymer to form a viscous gel
Implementation Method 2
a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile
Data Source
AI summary
An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having a Cmax to Cmin ratio of less than 200 and a lag time less than 0.2.